British Journal of Clinical Pharmacology · 2005 · 79 citations · 42 references
Life SciencesImmunologyPharmacologyAutoimmunityClinical ImmunologyInflammationAntioxidant DefenseAtherosclerosis PharmacotherapyLipid-lowering TherapyOxidative Damage To BiomoleculesOxidative StressReactive Oxygen SpeciesImmune Stress ResponseLdl Cholesterol LoweringOxidative BiomarkersOxidative Stress BiomarkersOxidative Stress In Cardiovascular DiseaseOxidative Stress InjuryPlasma Cholesterol LevelsSystemic Inflammation Markers
AIMS: To examine the effect of 24 weeks' rosuvastatin treatment on oxidative stress and changes in immune response to oxidized low-density lipoprotein (LDL). METHODS: This was an open-label study of patients in Austria receiving 10 or 40 mg rosuvastatin daily alternately during 12 and 24 weeks. Circulating concentrations of antibodies to malondialdehyde-oxidized LDL (MDA-LDL), both IgG and IgM type, to copper-oxidized LDL (Cu-OxLDL-IgG), concentrations of oxidized LDL complexed to IgG (OxLDL-IC) and markers of oxidative stress and systemic inflammation in subjects with plasma LDL cholesterol concentrations between 130 mg dl-1 and 250 mg dl-1 and triglycerides<or=400 mg dl-1 were determined. RESULTS: During statin therapy, plasma endogenous peroxides (POX-ACT) concentrations and peroxidase activity were significantly decreased, associated with a modest increase in total antioxidant capacity (TAC). Antibody titres to MDA-LDL-IgM, Cu-OxLDL-IgG and OxLDL-IC decreased, whereas MDA-LDL-IgG concentrations were increased after therapy. These changes were dose- and LDL-independent. POX-ACT concentrations were significantly positively correlated with inflammation markers before and after therapy and inversely with high-density lipoprotein-cholesterol concentrations after therapy. CONCLUSION: This study provides in vivo evidence that rosuvastatin significantly reduces oxidative stress and has immunomodulatory properties in a dose- and LDL-independent manner.
42
Prediction of Coronary Heart Disease Using Risk Factor Categories
Peter W.F. Wilson, Ralph B. D’Agostino, Daniel Levy et al. · Circulation · 1998 · 9.6K citations
Peter H. Jones, Michael H. Davidson, Evan A. Stein et al. · The American Journal of Cardiology · 2003 · 1.4K citations
Statins as a newly recognized type of immunomodulator
Brenda R. Kwak, Flore Mulhaupt, Samir Myit et al. · Nature Medicine · 2000 · 1.4K citations
Autoantibody against oxidised LDL and progression of carotid atherosclerosis
J T Salonen, H Korpela, R. Salonen et al. · The Lancet · 1992 · 1.3K citations · Full text